A study in rats and mice has found a cluster of brain cells where two of the body's own appetite-suppressing peptides can switch off eating without triggering nausea. That gap, between eating less and feeling sick, is one of the hardest things to engineer out of the current generation of obesity drugs. This work points at where in the brain it might come apart.
The cluster is the locus coeruleus, a small knot of noradrenaline-producing neurons in the brainstem better known for controlling arousal and stress than for hunger. Reporting online July 28 in Molecular Metabolism ↗, a team combined drugs, behavior tests, tissue staining, and genetic and chemogenetic switches to probe those cells. They showed that the neurons carry calcitonin receptors. Turning those receptors on, either with drugs or with engineered on-switches, sharply cut how much the animals ate and how much they weighed.
Appetite down, nausea absent
The part that matters is what did not happen. When the researchers activated the locus coeruleus calcitonin receptors, food intake and body weight fell, but the animals showed no sign of nausea and no change in the autonomic readouts that usually travel with it. Heart rate, body temperature, and the speed at which the stomach empties all held steady.
That is the separation the whole field wants. GLP-1 drugs like semaglutide ↗, and the amylin drugs now crowding behind them, all lean on brain circuits that suppress appetite partly by making food feel less appealing. A big share of that signal runs through pathways that also drive nausea and vomiting. Queasiness is why people titrate up slowly, why some cap out below the most effective dose, and why others quit. A brain site that lowers intake and leaves the sickness circuitry alone is exactly the kind of target that could widen that window.
Where amylin and CGRP fit
The receptors did not answer to just any signal. Using a technique that maps which genes are switched on inside single cells, the team found that the locus coeruleus calcitonin receptors sit alongside a partner protein called RAMP1. That adaptor lets a calcitonin receptor respond to two of the body's natural anorectic peptides: amylin, a fullness hormone from the pancreas, and CGRP, a nerve-signaling peptide. Inject either peptide straight into the locus coeruleus and the animals ate less, again without nausea.
Amylin is the more commercially loaded of the two. Drugmakers are racing to turn it into weight-loss medicine by engineering longer-lasting copies of the hormone. Novo Nordisk's cagrilintide ↗, a once-weekly amylin analog being developed alongside semaglutide, and Zealand Pharma's petrelintide ↗ are two of the candidates in that race. Both bet that this pathway can match GLP-1 on weight with a gentler side-effect profile. The new work offers a mechanistic reason to think appetite and nausea are separable at all. It also names a specific brain address where the split happens.
The caution that comes with mice
This is animal work, and the leap from a rat's locus coeruleus to a human appetite is long and littered with drugs that made the jump and failed. Switching a receptor on with a lab tool is also not the same as what a circulating drug does. A drug reaches the whole body and every receptor it fits. No existing amylin medicine is designed to hit the locus coeruleus specifically. Whether the benefit of these drugs runs partly through this site, or somewhere else entirely, is still unknown.
What the paper adds is a concrete node. It joins a recent line of work pinning the appetite and side-effect actions of these drugs to distinct brain regions rather than one blurred signal, a map peptidemodel has tracked before ↗ for the GIP receptor. The calcitonin receptor ↗ in the locus coeruleus is now on that map, marked as a place where eating and nausea can, at least in a mouse, be told apart.